Bard Exec Defends Handling Of Complaints At Vein Filter Trial

Law360, Phoenix (March 28, 2018, 11:19 PM EDT) -- A former quality-assurance executive at Bard Peripheral Vascular defended the company’s internal complaint-recording procedures Wednesday, the last day of evidence in a first bellwether trial over a vein implant that patients say was known to sometimes pierce through to other organs.

Former BPV vice president of quality assurance and current C.R. Bard Inc. Staff Vice President of Operations Chad Modra was the last witness to testify in the bellwether trial over injuries to Sherr-Una Booker, who says Bard’s G2 IVC filter — IVC for inferior vena cava, the body’s largest vein —was so prone to migrate, tilt, and perforate vein walls...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!